Ordinary Re-Weighting | RBC Biotech Opportunities NTR Index Series 2 | Effective Date 2nd January 2024
RBC Biotech Opportunities NTR Index Series 2:
In the ordinary re-weighting, the following composition will be implemented effective open 2nd January 2024:
| ABBVIE INC |
| AGIOS PHARMACEUTICALS INC |
| ALNYLAM PHARMACEUTICALS INC |
| AMGEN INC |
| BIOGEN INC |
| GILEAD SCIENCES INC |
| INCYTE CORP |
| INTRA-CELLULAR THERAPIES INC |
| KARUNA THERAPEUTICS INC |
| ELI LILLY & CO |
| PACIRA BIOSCIENCES INC |
| SAREPTA THERAPEUTICS INC |
| XENON PHARMACEUTICALS INC |